The NovaSeq X Series is Illumina's most powerful sequencing system, delivering an unprecedented combination of high throughput and accuracy, and featuring streamlined informatics, breakthrough ...
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...
StockStory.org on MSN
ILMN Q1 deep dive: Clinical sequencing fuels growth as NovaSeq X demand surges
Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results , with sales up 4.8% year on year to $1.09 billion. The ...
Illumina (ILMN) announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a software upgrade and new kits. The single-flow-cell NovaSeq X ...
Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the high-throughput machines more attractive to smaller laboratories. For its ...
Hosted on MSN
Mastering sequencing QC for flawless runs
From Illumina to Nanopore to PacBio, getting high-quality sequencing data starts long before the run begins. Careful library prep, accurate quantification, platform-specific QC checks, and novel RNA ...
With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance. It now ...
Illumina's NovaSeq 6000 stands as the latest breakthrough in ultra-high throughput NGS sequencing instrumentation. This dual flow cell instrument is meticulously designed to function with four ...
Oct 9 (Reuters) - Medical equipment maker Illumina (ILMN.O), opens new tab announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results